purerawz retatrutide – Pure Compounding Labs PureRawz Publishes 2026 Research Peptide

Programs run by the government for managing chronic diseases are likely to drive the regional market

Sustained Exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes

Tirzepatide, sold as Mounjaro, is a newer medication that targets two hormones: GLP-1 and GIP

Critical analysis of bariatric procedures in Prader-Willi syndrome

In Feb26, Hernexeos (zongertinib) received FDA accelerated approval for advanced HER2-mutant NSCLC, based on a 76% objective response rate (N=72) in the Beamion LUNG-1 study, following Breakthrough Therapy Designation and prior approval in August 2025